Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.

摘要: AbstractObjective:This study assessed the long-term cost effectiveness of rosuvastatin therapy compared with placebo in reducing incidence major cardiovascular (CVD) events and mortality.Methods:A probabilistic Monte Carlo simulation model estimated (20 mg daily) for prevention CVD mortality morbidity. The included three stages: (1) simulating 4 years JUPITER trial, (2) initial beyond (3) subsequent event prevention. A US payer perspective was reflecting direct medical costs, up to a lifetime horizon. Sensitivity analyses tested robustness estimates.Results:For hypothetical cohort 100,000 patients at moderate high risk based on Framingham ≥10%, quality-adjusted life-years (QALYs) gained 33,480 over horizon, 25,380 9916 20-year...